{
  "docId": "019de075-d8f1-727b-b893-5e9d6af9a579",
  "docSlug": "880c8a38f766d3eb6660c74e922f5744",
  "documentTitle": "MindMed | Investor Presentation Deck | 32 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 32,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide provides a high-level summary of the company's pipeline and financial runway.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d8f1-727b-b893-5e9d6af9a579/3",
  "deckHref": "/decks/019de075-d8f1-727b-b893-5e9d6af9a579",
  "deckJsonHref": "/decks/019de075-d8f1-727b-b893-5e9d6af9a579.json",
  "deckAnchorHref": "/decks/019de075-d8f1-727b-b893-5e9d6af9a579#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0018
      },
      "kind": "callout",
      "text": "Advancing Proprietary Drug Candidates Across Psychiatric Indications",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "916c0720-625d-48c4-94c0-77461ad7c254",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.1,
        "y": 0.003
      },
      "kind": "list",
      "text": "MM-120: Generalized Anxiety Disorder (GAD) & Attention-Deficit/Hyperactivity Disorder (ADHD); Well-characterized pharmacology; Accelerated development potential",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25357392-7052-4d1b-9c7f-52bada697b49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.55,
        "y": 0.003
      },
      "kind": "list",
      "text": "MM-402: Autism Spectrum Disorder (ASD); Enhanced pharmacology; Potential to overcome safety liabilities; Standard delivery / dosing model",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ec14b0e-fc57-4421-bcf4-851faf8e818e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.15,
        "y": 0.007
      },
      "kind": "list",
      "text": "Diversified pipeline of clinical programs targeting significant unmet medical needs; Pivotal inflection point with key clinical readout expected in Q4 2023; IP and R&D strategies intended to maximize market exclusivity and protection; Expected cash runway through key clinical readouts and into 2026",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d11f38b5-55b9-45d1-8920-47dcd49facc6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.1,
        "y": 0.0088
      },
      "kind": "source-note",
      "text": "1. The company's ending Q2 2023 cash and cash equivalents of $116.9 million and committed credit facility are expected to fund operations into 2026, if certain milestones are achieved that unlock additional capital",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd3adcaf-8a47-41b5-b461-2d7db2cc6fe1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "subtitle",
      "text": "Using industry-leading drug development expertise to unlock the full therapeutic potential of psychedelics and other novel product candidates",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d1bc0d3-dccd-43ef-8223-fefb7b22c1bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "MindMed at a Glance: A Global Leader in Brain Health",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8131e5a5-b617-40c5-bbe5-d9e4016c634a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.4,
        "y": 0.0065
      },
      "kind": "title",
      "text": "Business Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f296da44-f253-43e8-9481-aa9f09a5d56e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "68ca57a3-2d42-4632-b38e-d9cecf2c7446",
      "evidence": "This slide presents a concise overview of MindMed's current state, highlighting its diversified pipeline, key clinical programs, and financial situation.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}